2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2 manufacturers
|
| | 2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2 Basic information |
| Product Name: | 2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2 | | Synonyms: | PAR-2 AGONIST II;PROTEINASE ACTIVATED RECEPTOR-2 AGONIST II;2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2;2-(2-FUROYL)-LIGRLOAMIDE;2-(2-FUROYL)-PAR-2 (2-6)-ORN AMIDE (MOUSE, RAT);2F-LIGRLO-AMIDE;2-FUROYL-LEU-ILE-GLY-ARG-LEU-ORN-NH2;2-FUROYL-LIGRLO-AMIDE | | CAS: | 729589-58-6 | | MF: | C36H63N11O8 | | MW: | 777.96 | | EINECS: | | | Product Categories: | | | Mol File: | 729589-58-6.mol |  |
| | 2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2 Chemical Properties |
| density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | -20°C | | solubility | Soluble in H2O | | pka | 12.91±0.46(Predicted) | | form | powder | | color | white | | Water Solubility | Soluble to 1 mg/ml in water | | InChI | 1S/C17H16ClN3OS/c1-9-7-10(2)21-17-13(9)14(19)15(23-17)16(22)20-8-11-3-5-12(18)6-4-11/h3-7H,8,19H2,1-2H3,(H,20,22) | | InChIKey | FPRULFHDSFKYBV-UHFFFAOYSA-N | | SMILES | Cc1cc(C)c2c(N)c(sc2n1)C(=O)NCc3ccc(Cl)cc3 |
| Hazard Codes | Xi | | Risk Statements | 36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Eye Irrit. 2
Skin Irrit. 2
STOT SE 3 |
| | 2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2 Usage And Synthesis |
| Uses | 2-Furoyl-LIGRLO-amide trifluoroacetate salt may be used as a protease-activated receptor 2 (PAR2) agonist in endothelial progenitor cells (EPCs) and in transient receptor potential cation channel subfamily V member (TRPV4)-transfected HEK293t cells. | | General Description | 2-Furoyl-LIGRLO-amide trifluoroacetate salt is a peptide that acts as a proteinase-activated receptor-2 (PAR2) agonist, and contains a furoyl group addition at its N-terminal. | | Biological Activity | potent and selective par2 receptor agonist (pd2 = 7.0). causes a dose-dependent relaxation of murine femoral arteries. | | Biochem/physiol Actions | 2-Furoyl-LIGRLO-amide is a potent and selective protease-activated receptor 2 (PAR2) agonist. PAR-2 activation is associated with increases in cAMP and intracellular Ca(2+). Immunoblot analysis revealed increases in phosphorylation of epidermal growth factor (EGF) receptor (EGFR) tyrosine kinase, Src, Pyk2, cRaf, and ERK1/2 in response to PAR-2 activation. 2-Furoyl-LIGRLO-amide is nearly 100-fold more potent than SLIGRL-NH2 (Cat. No. S9317). 2-Furoyl-LIGRLO-amide caused both an endothelium-dependent relaxation and an endothelium-independent contraction. It produced delayed (6 hours later) facilitation of capsaicin-evoked visceral nociception, an effect being much more potent than SLIGRL-NH2. Such effects were mimicked by i.col. trypsin. 2-f-LIGRL-NH2, coadministered repeatedly with caerulein six times in total, abolished the caerulein-evoked abdominal hyperalgesia/allodynia in WT, but not PAR2-KO, mice. Repeated doses of 2-f-LIGRL-NH2 moderately attenuated the severity of caerulein-induced pancreatitis in WT animals. It induced a similar dose-dependent increase in Ca2 levels in the presence and absence of b-arrestins. | | storage | Store at -20°C |
| | 2-(2-FUROYL)-LEU-ILE-GLY-ARG-LEU-ORN-NH2 Preparation Products And Raw materials |
|